Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections

INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Cassie L., Turner, Michelle S., Frens, Jeremy J., Snider, Cynthia B., Smith, Jordan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446369/
https://www.ncbi.nlm.nih.gov/pubmed/28386776
http://dx.doi.org/10.1007/s40121-017-0156-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446369/
https://www.ncbi.nlm.nih.gov/pubmed/28386776
http://dx.doi.org/10.1007/s40121-017-0156-z

Ejemplares similares